Hospital
Sentara Hospitals
Sentara Hospitals was paid $88.20M by Medicaid between Jan 2018 and Dec 2024, across 663 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
NORFOLK, VA 23507
NORFOLK, VA 23507
33aNPI1437119310assigned 03/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$88.20M
24GClaims4,190,266
24DCodes billed663
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#3 of 80
Median peer was paid$14.69M
This provider vs. median6.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 560,468 | $5.28M | |
| 2019 | 789,528 | $8.31M | |
| 2020 | 767,279 | $13.92M | |
| 2021 | 809,470 | $16.42M | |
| 2022 | 450,301 | $15.49M | |
| 2023 | 527,991 | $18.78M | |
| 2024incomplete | 285,229 | $9.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 60,111 | 47,391 | $9.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 62,221 | 50,524 | $9.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 49,416 | 38,498 | $8.15M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 22,306 | 15,311 | $6.05M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 18,341 | 15,445 | $3.42M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 64,010 | 15,413 | $3.03M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 20,037 | 14,423 | $2.58M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 16,899 | 14,513 | $2.34M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.1% | 2,578 | 2,186 | $1.82M |
| 59025 | Fetal non-stress test | 1.8% | 8,743 | 6,471 | $1.62M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 6,815 | 3,741 | $1.50M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 12,938 | 7,997 | $1.39M |
651 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 5,977 | $1.36M |
| G0378 | Hospital observation service, per hour | 1.4% | 7,015 | $1.25M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,430 | $979K |
| J2357 | Injection, omalizumab, 5 mg | 1.1% | 3,749 | $956K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 7,169 | $889K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 686 | $866K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25,522 | $806K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 3,916 | $775K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,675 | $752K |
| 96415 | <1% | 3,450 | $749K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 593 | $732K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,771 | $635K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,600 | $604K |
| 97161 | <1% | 6,814 | $596K | |
| 36512 | <1% | 447 | $558K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,107 | $550K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,719 | $547K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 136,919 | $472K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 798 | $470K |
| 80053 | Comprehensive metabolic panel | <1% | 124,468 | $465K |
| J3490 | Unclassified drugs | <1% | 410,213 | $439K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,017 | $438K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 2,788 | $431K |
| 36430 | <1% | 3,692 | $411K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 755 | $386K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,402 | $371K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,250 | $359K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,386 | $354K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,454 | $344K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,922 | $336K |
| 97162 | <1% | 3,441 | $332K | |
| 93458 | <1% | 237 | $326K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,069 | $323K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 78,931 | $313K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,255 | $297K |
| 76830 | Ultrasound, transvaginal | <1% | 3,659 | $289K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,313 | $271K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,681 | $269K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 17,074 | $269K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16,823 | $268K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 542 | $249K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,352 | $245K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 37,677 | $244K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,675 | $237K |
| 76642 | <1% | 2,439 | $236K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,569 | $234K |
| 99201 | <1% | 2,349 | $233K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 475 | $230K |
| 75574 | <1% | 756 | $220K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,780 | $218K |
| J0485 | Injection, belatacept, 1 mg | <1% | 925 | $215K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 3,342 | $214K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 191,952 | $210K |
| 93971 | <1% | 2,731 | $208K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 75,111 | $207K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,098 | $203K |
| 93970 | <1% | 1,928 | $198K | |
| 70491 | <1% | 1,403 | $195K | |
| 10060 | <1% | 1,702 | $193K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,356 | $189K |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 15 | $187K |
| 72141 | <1% | 1,084 | $186K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41,457 | $185K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,411 | $180K |
| 77386 | <1% | 489 | $177K | |
| 59050 | <1% | 1,076 | $176K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 8,816 | $176K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 52,355 | $172K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 78,824 | $171K |
| 80061 | Lipid panel | <1% | 74,544 | $164K |
| 97165 | <1% | 2,602 | $161K | |
| 74183 | <1% | 610 | $160K | |
| 71250 | <1% | 2,790 | $153K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 53,974 | $147K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,615 | $145K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 65,208 | $145K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,093 | $143K |
| 76770 | <1% | 1,520 | $138K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,553 | $136K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 55,652 | $135K |
| 0240U | <1% | 2,090 | $128K | |
| 97116 | <1% | 5,644 | $127K | |
| 77336 | <1% | 2,245 | $123K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 200 | $121K |
| 97113 | <1% | 2,724 | $121K | |
| 83880 | <1% | 14,447 | $120K | |
| 76801 | <1% | 2,710 | $120K | |
| 87536 | <1% | 6,418 | $119K | |
| 93017 | <1% | 1,575 | $113K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,850 | $107K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,063 | $104K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,236 | $102K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 207 | $92K |
| 95806 | <1% | 164 | $91K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,913 | $90K |
| 19318 | <1% | 12 | $88K | |
| 86923 | <1% | 4,611 | $87K | |
| 93451 | <1% | 55 | $86K | |
| 70496 | <1% | 328 | $85K | |
| 49083 | <1% | 173 | $84K | |
| 70486 | <1% | 2,685 | $81K | |
| 97016 | <1% | 2,670 | $75K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,949 | $71K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,988 | $71K |
| 85027 | <1% | 54,839 | $70K | |
| 12001 | <1% | 314 | $64K | |
| 94660 | <1% | 204 | $61K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 305 | $61K |
| 87481 | <1% | 15,155 | $58K | |
| 94060 | <1% | 1,439 | $58K | |
| 43235 | <1% | 106 | $58K | |
| 80076 | <1% | 35,084 | $58K | |
| 88185 | <1% | 1,407 | $55K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 82 | $55K |
| 80047 | <1% | 16,459 | $55K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 16,444 | $54K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,738 | $53K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,179 | $53K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 60,691 | $51K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,036 | $51K |
| 82962 | <1% | 46,774 | $50K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,567 | $50K |
| 74174 | <1% | 378 | $50K | |
| 82607 | <1% | 17,747 | $49K | |
| 73610 | <1% | 4,429 | $48K | |
| 97166 | <1% | 459 | $48K | |
| 94799 | <1% | 4,403 | $47K | |
| 94618 | <1% | 743 | $46K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15,093 | $46K |
| 84439 | <1% | 24,010 | $46K | |
| 72197 | <1% | 139 | $45K | |
| 85379 | <1% | 9,766 | $44K | |
| 90715 | <1% | 3,075 | $44K | |
| 97035 | <1% | 864 | $44K | |
| 86780 | <1% | 26,809 | $44K | |
| 82728 | <1% | 19,257 | $43K | |
| 93296 | <1% | 2,503 | $43K | |
| 84484 | <1% | 36,553 | $43K | |
| 12002 | <1% | 210 | $42K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 34,747 | $42K |
| 86703 | <1% | 33,597 | $41K | |
| 83970 | <1% | 5,328 | $40K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 210 | $40K |
| 88142 | <1% | 13,021 | $37K | |
| 94729 | <1% | 2,441 | $37K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,214 | $37K |
| 86828 | <1% | 1,875 | $37K | |
| 73590 | <1% | 2,696 | $36K | |
| 76937 | <1% | 1,354 | $36K | |
| 86361 | <1% | 5,603 | $36K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,036 | $35K |
| 86803 | <1% | 20,019 | $35K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 48,341 | $34K |
| 73030 | <1% | 4,142 | $34K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 412 | $34K |
| 86850 | <1% | 23,301 | $34K | |
| 86900 | <1% | 25,596 | $33K | |
| 36561 | <1% | 14 | $32K | |
| 94726 | <1% | 1,581 | $32K | |
| 86922 | <1% | 2,060 | $31K | |
| 88307 | <1% | 2,146 | $30K | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 13 | $30K |
| 72110 | <1% | 1,878 | $29K | |
| 87040 | <1% | 5,292 | $29K | |
| 73130 | <1% | 3,739 | $29K | |
| 77412 | <1% | 415 | $29K | |
| 73552 | <1% | 1,609 | $28K | |
| 93880 | <1% | 448 | $28K | |
| 64400 | <1% | 138 | $28K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,325 | $28K |
| 80055 | <1% | 5,090 | $28K | |
| 77334 | <1% | 342 | $28K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15,030 | $28K |
| 73564 | <1% | 4,468 | $27K | |
| 84153 | <1% | 6,518 | $27K | |
| 81001 | <1% | 71,794 | $27K | |
| 86235 | <1% | 4,265 | $27K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 704 | $27K |
| 83735 | <1% | 26,233 | $26K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,791 | $26K |
| 83020 | <1% | 6,703 | $25K | |
| 82746 | <1% | 11,111 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,812 | $25K |
| 99234 | <1% | 801 | $25K | |
| 73630 | <1% | 4,213 | $25K | |
| 83550 | <1% | 17,861 | $25K | |
| 73502 | <1% | 2,475 | $24K | |
| 93798 | <1% | 271 | $24K | |
| 77290 | <1% | 115 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 37,941 | $24K |
| 86920 | <1% | 2,418 | $23K | |
| 97014 | <1% | 945 | $22K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,162 | $22K |
| 82043 | <1% | 17,059 | $22K | |
| 73560 | <1% | 993 | $22K | |
| 82565 | <1% | 12,587 | $21K | |
| 83540 | <1% | 19,697 | $21K | |
| 36000 | <1% | 985 | $21K | |
| 87077 | <1% | 23,418 | $21K | |
| C1729 | Catheter, drainage | <1% | 2,155 | $21K |
| 86003 | <1% | 2,127 | $20K | |
| 84702 | <1% | 16,279 | $20K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 2,057 | $20K |
| 86832 | <1% | 1,797 | $20K | |
| 85014 | <1% | 18,087 | $20K | |
| 88341 | <1% | 1,494 | $19K | |
| 73110 | <1% | 2,295 | $19K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,595 | $19K |
| 86833 | <1% | 1,800 | $19K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 37,945 | $18K |
| 70498 | <1% | 303 | $18K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 2,989 | $18K |
| 87340 | <1% | 20,664 | $17K | |
| 93308 | <1% | 46 | $17K | |
| 94010 | <1% | 633 | $17K | |
| 85610 | <1% | 17,583 | $16K | |
| 86140 | <1% | 9,919 | $16K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,869 | $16K |
| 96376 | <1% | 15,614 | $16K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 19 | $15K |
| 84703 | <1% | 14,752 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 22,447 | $14K |
| 77470 | <1% | 34 | $14K | |
| 97018 | <1% | 574 | $14K | |
| 86921 | <1% | 2,053 | $14K | |
| 86901 | <1% | 25,597 | $14K | |
| 84100 | <1% | 13,679 | $14K | |
| 76536 | <1% | 157 | $14K | |
| 96367 | <1% | 767 | $14K | |
| 73562 | <1% | 1,754 | $14K | |
| 84403 | <1% | 3,349 | $14K | |
| 80069 | <1% | 3,204 | $13K | |
| 76882 | <1% | 218 | $13K | |
| 77300 | <1% | 183 | $13K | |
| 82677 | <1% | 2,654 | $13K | |
| 80074 | <1% | 2,389 | $13K | |
| 87186 | <1% | 16,123 | $12K | |
| 87902 | <1% | 375 | $12K | |
| 87529 | <1% | 1,061 | $12K | |
| 12011 | <1% | 87 | $12K | |
| 86480 | <1% | 1,360 | $12K | |
| 82024 | <1% | 853 | $12K | |
| 80197 | <1% | 5,029 | $12K | |
| 84481 | <1% | 5,846 | $12K | |
| 82105 | <1% | 6,518 | $11K | |
| 72190 | <1% | 216 | $11K | |
| 73080 | <1% | 1,344 | $11K | |
| 84402 | <1% | 2,077 | $11K | |
| 86300 | <1% | 1,541 | $11K | |
| 72100 | <1% | 989 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,233 | $11K |
| 87497 | <1% | 2,685 | $10K | |
| 84145 | <1% | 977 | $10K | |
| 84146 | <1% | 3,634 | $10K | |
| 73090 | <1% | 1,118 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 884 | $10K |
| C1769 | Guide wire | <1% | 5,599 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,109 | $10K |
| 83516 | <1% | 3,030 | $10K | |
| 29125 | <1% | 74 | $10K | |
| 81003 | <1% | 21,129 | $9K | |
| 80164 | <1% | 2,285 | $9K | |
| 97760 | <1% | 208 | $9K | |
| 88184 | <1% | 705 | $9K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 60 | $9K |
| 71271 | <1% | 104 | $9K | |
| 83690 | <1% | 23,668 | $9K | |
| 93976 | <1% | 291 | $9K | |
| 86160 | <1% | 1,819 | $9K | |
| 83605 | <1% | 7,719 | $9K | |
| 93922 | <1% | 204 | $9K | |
| 82784 | <1% | 3,340 | $9K | |
| 86038 | <1% | 4,475 | $9K | |
| 78803 | <1% | 17 | $9K | |
| 92610 | <1% | 153 | $8K | |
| 83001 | <1% | 3,476 | $8K | |
| 83615 | <1% | 8,314 | $8K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,005 | $8K |
| 87070 | <1% | 6,920 | $8K | |
| 87150 | <1% | 5,102 | $8K | |
| 99205 | Prolong outpt/office vis | <1% | 87 | $8K |
| 36600 | <1% | 975 | $8K | |
| 77080 | <1% | 238 | $8K | |
| 85018 | <1% | 8,029 | $8K | |
| 87081 | <1% | 12,799 | $8K | |
| 82330 | <1% | 3,514 | $8K | |
| 74178 | <1% | 26 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,394 | $8K |
| 86706 | <1% | 5,122 | $8K | |
| 81025 | <1% | 27,625 | $8K | |
| 86317 | <1% | 2,198 | $8K | |
| 86902 | <1% | 2,056 | $7K | |
| 85652 | <1% | 11,471 | $7K | |
| 82533 | <1% | 1,346 | $7K | |
| 93923 | <1% | 136 | $7K | |
| 74018 | <1% | 771 | $7K | |
| C1757 | Catheter, thrombectomy/embolectomy | <1% | 167 | $7K |
| 82670 | <1% | 1,882 | $7K | |
| 84550 | <1% | 9,714 | $7K | |
| 86334 | <1% | 1,604 | $7K | |
| 90686 | <1% | 853 | $7K | |
| 88342 | <1% | 2,984 | $7K | |
| 83721 | <1% | 2,814 | $7K | |
| 82570 | <1% | 7,041 | $7K | |
| 87109 | <1% | 964 | $6K | |
| 73060 | <1% | 630 | $6K | |
| 0225U | <1% | 80 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 21 | $6K |
| 82378 | <1% | 1,089 | $6K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 5,523 | $6K |
| 95811 | <1% | 19 | $6K | |
| 83883 | <1% | 1,349 | $6K | |
| 82947 | <1% | 2,055 | $6K | |
| 72050 | <1% | 367 | $6K | |
| 72158 | <1% | 39 | $6K | |
| 88304 | <1% | 1,865 | $6K | |
| 73700 | <1% | 59 | $6K | |
| 83002 | <1% | 2,625 | $5K | |
| 86696 | <1% | 2,993 | $5K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 22 | $5K |
| 86593 | <1% | 2,342 | $5K | |
| 92083 | <1% | 970 | $5K | |
| 84425 | <1% | 1,660 | $5K | |
| 86225 | <1% | 2,642 | $5K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 13 | $5K |
| 86360 | <1% | 531 | $5K | |
| 82550 | <1% | 5,627 | $5K | |
| 82077 | <1% | 15,149 | $5K | |
| 94727 | <1% | 262 | $5K | |
| 85730 | <1% | 7,357 | $5K | |
| 86695 | <1% | 2,619 | $5K | |
| 87255 | <1% | 1,086 | $5K | |
| 86147 | <1% | 890 | $5K | |
| 97167 | <1% | 90 | $5K | |
| 73140 | <1% | 539 | $5K | |
| 80177 | <1% | 1,286 | $4K | |
| 92250 | <1% | 1,121 | $4K | |
| 85384 | <1% | 3,784 | $4K | |
| 84450 | <1% | 5,482 | $4K | |
| 84156 | <1% | 6,668 | $4K | |
| 84445 | <1% | 391 | $4K | |
| 86376 | <1% | 1,732 | $4K | |
| 82950 | <1% | 8,200 | $4K | |
| 87205 | <1% | 6,406 | $4K | |
| 84436 | <1% | 2,853 | $4K | |
| 86705 | <1% | 3,256 | $4K | |
| 84460 | <1% | 4,976 | $4K | |
| 86431 | <1% | 3,825 | $4K | |
| 82652 | <1% | 837 | $4K | |
| 84520 | <1% | 4,766 | $4K | |
| 87625 | <1% | 1,391 | $4K | |
| 88112 | <1% | 306 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 14,686 | $4K |
| 87210 | <1% | 13,677 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15,562 | $4K |
| 87563 | <1% | 1,142 | $4K | |
| 87799 | <1% | 1,556 | $3K | |
| 82785 | <1% | 1,482 | $3K | |
| 86704 | <1% | 1,912 | $3K | |
| 75561 | <1% | 12 | $3K | |
| 80143 | <1% | 785 | $3K | |
| 86200 | <1% | 1,915 | $3K | |
| 76870 | <1% | 44 | $3K | |
| 92020 | <1% | 13 | $3K | |
| 83921 | <1% | 685 | $3K | |
| 82274 | <1% | 833 | $3K | |
| 97163 | <1% | 95 | $3K | |
| 20610 | <1% | 31 | $3K | |
| 86769 | <1% | 547 | $3K | |
| 86256 | <1% | 996 | $3K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 800 | $3K |
| 84165 | <1% | 1,470 | $3K | |
| 82627 | <1% | 1,025 | $3K | |
| 83520 | <1% | 875 | $3K | |
| 86677 | <1% | 920 | $3K | |
| 84480 | <1% | 1,051 | $3K | |
| 84681 | <1% | 566 | $3K | |
| 80320 | <1% | 1,864 | $3K | |
| 83655 | <1% | 2,262 | $3K | |
| 86708 | <1% | 1,139 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,785 | $2K |
| 86146 | <1% | 220 | $2K | |
| 86039 | <1% | 1,738 | $2K | |
| 86709 | <1% | 2,377 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 695 | $2K |
| 82150 | <1% | 1,516 | $2K | |
| 81329 | <1% | 500 | $2K | |
| 83718 | <1% | 1,356 | $2K | |
| 87530 | <1% | 364 | $2K | |
| 86800 | <1% | 1,149 | $2K | |
| 85045 | <1% | 2,441 | $2K | |
| 78580 | <1% | 13 | $2K | |
| 87517 | <1% | 215 | $2K | |
| 86336 | <1% | 2,985 | $2K | |
| 87449 | <1% | 978 | $2K | |
| 82803 | <1% | 1,911 | $2K | |
| 72040 | <1% | 80 | $2K | |
| 80178 | <1% | 780 | $2K | |
| 88360 | <1% | 114 | $2K | |
| 82465 | <1% | 2,347 | $2K | |
| 36591 | <1% | 250 | $2K | |
| 87209 | <1% | 545 | $2K | |
| 83010 | <1% | 859 | $2K | |
| 86870 | <1% | 772 | $2K | |
| 86762 | <1% | 4,557 | $2K | |
| 82140 | <1% | 784 | $2K | |
| 85460 | <1% | 268 | $2K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 11,903 | $2K |
| 84154 | <1% | 384 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,934 | $2K |
| 86592 | <1% | 1,441 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 37 | $2K |
| 82553 | <1% | 456 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 26 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,783 | $2K |
| 80179 | <1% | 707 | $2K | |
| 80185 | <1% | 552 | $2K | |
| 81243 | <1% | 483 | $2K | |
| 82977 | <1% | 1,383 | $2K | |
| 86618 | <1% | 454 | $2K | |
| 84132 | <1% | 2,384 | $2K | |
| 82951 | <1% | 1,612 | $2K | |
| 93975 | <1% | 28 | $1K | |
| 92134 | <1% | 1,178 | $1K | |
| 84144 | <1% | 723 | $1K | |
| 80202 | <1% | 375 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,485 | $1K |
| 86787 | <1% | 1,962 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,161 | $1K |
| 80156 | <1% | 400 | $1K | |
| 85378 | <1% | 217 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 859 | $1K |
| 83525 | <1% | 764 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| 82040 | <1% | 1,530 | $1K | |
| 82985 | <1% | 223 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,388 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 965 | $1K |
| 82248 | <1% | 1,280 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 645 | $1K |
| 87427 | <1% | 676 | $1K | |
| 86341 | <1% | 175 | $1K | |
| 88271 | <1% | 39 | $1K | |
| 88275 | <1% | 37 | $1K | |
| 70355 | <1% | 138 | $1K | |
| 86694 | <1% | 689 | $1K | |
| 82164 | <1% | 532 | $1K | |
| 84478 | <1% | 1,076 | $1K | |
| 84479 | <1% | 800 | $1K | |
| 92526 | <1% | 38 | $1K | |
| 83498 | <1% | 399 | $1K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 2,615 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,254 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,784 | $987.13 |
| 87045 | <1% | 675 | $981.95 | |
| 87899 | <1% | 378 | $976.82 | |
| 97129 | <1% | 46 | $976.37 | |
| 81596 | <1% | 31 | $920.06 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 13 | $907.24 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 61 | $884.78 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 379 | $879.51 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,868 | $859.18 |
| 77012 | <1% | 48 | $858.11 | |
| 51798 | <1% | 67 | $846.86 | |
| 87102 | <1% | 888 | $786.12 | |
| 77417 | <1% | 44 | $779.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,883 | $777.91 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 5,780 | $766.76 |
| 82310 | <1% | 2,950 | $762.15 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,872 | $737.81 |
| 73000 | <1% | 31 | $731.82 | |
| 90656 | <1% | 47 | $730.65 | |
| 87046 | <1% | 680 | $726.66 | |
| 85613 | <1% | 505 | $723.99 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,047 | $721.04 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $702.88 |
| 87116 | <1% | 78 | $688.57 | |
| 77002 | <1% | 29 | $680.86 | |
| 83013 | <1% | 95 | $647.21 | |
| 87177 | <1% | 495 | $631.15 | |
| 82247 | <1% | 616 | $618.57 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,894 | $614.17 |
| 85046 | <1% | 1,983 | $601.27 | |
| 82390 | <1% | 238 | $591.92 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,947 | $575.68 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 602 | $571.14 |
| 82172 | <1% | 109 | $567.71 | |
| 84075 | <1% | 472 | $566.01 | |
| 86141 | <1% | 194 | $558.12 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 30 | $541.13 |
| 0012A | <1% | 29 | $519.63 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 6,612 | $514.59 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,294 | $504.29 |
| 86735 | <1% | 354 | $497.65 | |
| 92133 | <1% | 1,041 | $492.65 | |
| 87075 | <1% | 440 | $480.00 | |
| 82107 | <1% | 30 | $475.39 | |
| 93282 | <1% | 32 | $465.19 | |
| 85660 | <1% | 782 | $454.54 | |
| 89051 | <1% | 291 | $452.93 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,708 | $452.20 |
| 74220 | <1% | 15 | $448.07 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 60 | $436.80 |
| 86304 | <1% | 112 | $435.26 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 218 | $423.99 |
| 84466 | <1% | 236 | $406.48 | |
| 80175 | <1% | 118 | $405.92 | |
| 86765 | <1% | 375 | $370.04 | |
| 80183 | <1% | 95 | $364.25 | |
| 82952 | <1% | 1,324 | $363.65 | |
| 88173 | <1% | 97 | $351.24 | |
| 82103 | <1% | 118 | $342.94 | |
| 87076 | <1% | 456 | $342.71 | |
| 88172 | <1% | 13 | $342.39 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 81 | $308.78 |
| J2704 | Injection, propofol, 10 mg | <1% | 14,694 | $304.99 |
| 0011A | <1% | 32 | $288.08 | |
| 80329 | <1% | 21 | $274.17 | |
| 85049 | <1% | 813 | $267.04 | |
| 92015 | Determination of refractive state | <1% | 67 | $256.38 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,920 | $256.30 |
| 82010 | <1% | 869 | $255.08 | |
| 82672 | <1% | 37 | $254.96 | |
| 87338 | <1% | 56 | $249.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 384 | $246.39 |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 100 | $238.66 |
| 86162 | <1% | 85 | $236.88 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 18 | $236.69 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,240 | $235.83 |
| 86880 | <1% | 214 | $218.54 | |
| 77001 | <1% | 97 | $215.43 | |
| 86644 | <1% | 69 | $192.95 | |
| 83835 | <1% | 27 | $179.65 | |
| 82668 | <1% | 27 | $164.95 | |
| 72072 | <1% | 16 | $159.73 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,976 | $152.88 |
| 88311 | <1% | 32 | $148.28 | |
| 88312 | <1% | 14 | $122.24 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,750 | $119.01 |
| 84163 | <1% | 180 | $114.65 | |
| 36410 | <1% | 60 | $112.51 | |
| 82239 | <1% | 42 | $108.89 | |
| 82088 | <1% | 15 | $101.46 | |
| 82575 | <1% | 101 | $98.78 | |
| 87329 | <1% | 56 | $98.74 | |
| 87206 | <1% | 193 | $95.48 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | <1% | 67 | $90.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,982 | $87.87 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,062 | $86.75 |
| 86301 | <1% | 14 | $86.56 | |
| 81401 | <1% | 42 | $84.76 | |
| 85347 | <1% | 783 | $81.02 | |
| 86255 | <1% | 29 | $80.80 | |
| 84134 | <1% | 98 | $80.30 | |
| 51702 | <1% | 13 | $79.91 | |
| 72070 | <1% | 12 | $77.85 | |
| 91301 | <1% | 14 | $75.58 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,143 | $74.48 |
| 81374 | <1% | 12 | $66.90 | |
| 82397 | <1% | 28 | $60.77 | |
| 82085 | <1% | 27 | $60.48 | |
| 87521 | Neg quan hep c or qual rna | <1% | 47 | $60.42 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 684 | $58.17 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,092 | $56.08 |
| 86707 | <1% | 31 | $53.22 | |
| 83993 | <1% | 12 | $53.01 | |
| 86617 | <1% | 26 | $49.79 | |
| 82525 | <1% | 12 | $49.17 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,164 | $44.73 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 63 | $42.41 |
| 87350 | <1% | 26 | $41.52 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 893 | $40.00 |
| 85048 | <1% | 16 | $36.64 | |
| 86665 | <1% | 113 | $36.47 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 418 | $35.52 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,504 | $34.77 |
| 36592 | <1% | 61 | $33.12 | |
| C1758 | Catheter, ureteral | <1% | 59 | $32.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 196 | $30.93 |
| 90674 | <1% | 28 | $29.66 | |
| 85240 | <1% | 13 | $27.80 | |
| 86328 | <1% | 28 | $24.53 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,137 | $24.16 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 527 | $23.03 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 68 | $18.15 |
| 84300 | <1% | 18 | $17.74 | |
| 80299 | <1% | 43 | $15.79 | |
| 82272 | <1% | 176 | $14.21 | |
| 85245 | <1% | 14 | $13.89 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 517 | $11.96 |
| 86645 | <1% | 14 | $10.93 | |
| 86308 | <1% | 13 | $10.38 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 155 | $7.99 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 382 | $6.44 |
| 84295 | <1% | 20 | $4.82 | |
| 89055 | <1% | 16 | $3.97 | |
| 82945 | <1% | 18 | $3.54 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 84 | $3.16 |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 163 | $2.67 |
| 84432 | <1% | 15 | $2.05 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 757 | $1.74 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 25 | $1.14 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 106 | $0.38 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 144 | $0.24 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 366 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 310 | $0.01 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 187 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 632 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 41 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 53 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 299 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 17 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 591 | $0.00 |
| 88333 | 0% | 50 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 272 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 14 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 94 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 438 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 30 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 89 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 55 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 14 | $0.00 |
| 76376 | 0% | 175 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 16 | $0.00 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 15 | $0.00 |
| 88313 | 0% | 17 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 419 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 54 | $0.00 |
| 86663 | 0% | 13 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 591 | $0.00 |
| 36416 | 0% | 384 | $0.00 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 209 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 85 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 367 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 32 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 452 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 26 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 36 | $0.00 |
| 88331 | 0% | 12 | $0.00 | |
| 72170 | 0% | 40 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 27 | $0.00 |
| 73660 | 0% | 14 | $0.00 | |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 0% | 68 | $0.00 |
| 84157 | 0% | 19 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 39 | $0.00 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 0% | 19 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 28 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 29 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 14 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 17 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.